截至2025年11月3日收盘，皓宸医疗（002622）报收于3.46元，较前一交易日上涨3.9%，最新总市值为 29.06亿元。该股当日开盘3.33元，最高3.5元，最低3.31元，成交额达1.58亿元，换手率为5.53%。 公司近日发布公告称，皓宸医疗科技股份有限公司于2025年10月30日收到控股孙公司德伦医疗转发的吉 林市船营区人民法院相关法律文书，案号为（2025）吉0204民初4757号。原告为浙江浙捌仙女湖企业管 理合伙企业（有限合伙），被告为公司、全资子公司植钰医疗及控股子公司德伦医疗。本案系债权人撤 销权纠纷，原告诉请撤销公司将其持有的德伦医疗51%股权无偿转让给植钰医疗的行为，并要求恢复股 权登记。法院已裁定冻结植钰医疗持有的德伦医疗51%股权，对应出资额2,652万元，冻结期限两年。 德伦医疗2024年度营业收入占公司总营收的89.78%。判决结果预计不会对公司本期或期后利润造成直 接影响，但存在被司法处置的风险，可能影响生产经营。公司表示将积极协商解决债务问题。 最新公告列表 《关于控股孙公司收到法院传票及《民事裁定书》的公告》 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备 ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2025-029 皓宸医疗科技股份有限公司 关于控股孙公司收到法院传票及《民事裁定书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、案件所处的诉讼阶段：收到传票，尚未开庭审理。 2、上市公司所处的当事人地位：皓宸医疗科技股份有限公司（以下简称"公司"）、 全资子公司植钰医疗投资有限公司（以下简称"植钰医疗"）及其控股子公司广东德伦医 疗集团有限公司（以下简称"德伦医疗"）为被告。 3、涉案的金额：植钰医疗持有的德伦医疗股权，持股比例为 51%，对应出资额为 2,652 万元。 4、对上市公司损益产生的影响：本次诉讼所涉及为债权人转让撤销权纠纷，其判决 结果预计不会对公司本期利润或期后利润造成直接影响。若法院对该案采取进一步措施， 则可能存在被司法处置的风险，可能对公司及子公司的生产经营产生一定的影响。 公司于 2025 年 10 月 30 日收到控股孙公司德伦医疗转发的吉林市船营区人民 法院出具的案号（2025）吉 0204 民初 4757 号《传票》《民事裁定书》《民事起诉 状》 ...

皓宸医疗成立于1998年11月6日，于2011年10月18日在深圳证券交易所上市，注册地址位于吉林省，办公 地址位于北京市。该公司是一家涉足医疗服务领域的企业，其口腔医疗服务具有一定的市场竞争力。 公司主营业务包括永磁开关及高低压开关成套设备产品的研发、生产和销售业务以及口腔医疗服务业务。 所属申万行业为医药生物 - 医疗服务 - 医院，所属概念板块有医疗美容、民营医院、金融科技核聚变、超 导概念、核电。 偿债能力方面，2025年三季度皓宸医疗资产负债率为71.72%，高于去年同期的68.55%，也高于行业平均的 46.74%。从盈利能力看，2025年三季度公司毛利率为47.72%，略低于去年同期的47.97%，但高于行业平均 的31.10%。 经营业绩：营收行业第十四，净利润第十三 2025年三季度，皓宸医疗营业收入为5.27亿元，行业排名14/15，远低于行业第一名爱尔眼科的174.84亿元 和第二名美年健康的69.25亿元，也低于行业平均数29.66亿元和中位数13.6亿元。主营业务构成中，医疗口 腔服务收入2.88亿元，占比91.98%；实业开关产品收入2411.29万元，占比7.69%；其他收入10 ...

证券代码：002622 证券简称：皓宸医疗 公告编号：2025-027 经与会董事认真审议并表决，通过了以下议案： 一、审议通过《关于 2025 年第三季度报告的议案》 表决情况：同意 7 票，反对 0 票，弃权 0 票； 表决结果：通过。 本议案已经公司审计委员会审议并取得了明确同意的意见。 皓宸医疗科技股份有限公司 第五届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 皓宸医疗科技股份有限公司（以下简称"公司"）第五届董事会第十六次会 议于 2025 年 10 月 30 日上午 10:00 在公司会议室以现场结合通讯表决方式召开。 召开本次会议的通知已于 2025 年 10 月 19 日以电话、电子邮件等方式通知了各 位董事，会议应参加表决董事 7 名，实际参加表决董事 7 名。此次会议的召集、 召开与表决程序符合《中华人民共和国公司法》和《公司章程》及相关法律、法 规的规定，合法有效。 1、《皓宸医疗科技股份有限公司第五届董事会第十六次会议决议》。 特此公告。 皓宸医疗科技股份有限公司董事会 二〇二五年十月三十日 《2025 ...

Core Insights - Haocen Medical reported a decline in revenue and an increase in net loss for the third quarter and the first three quarters of the year [1] Financial Performance - In Q3, the company achieved operating revenue of 213.26 million yuan, a year-on-year decrease of 15.72% [1] - The net loss attributable to shareholders for Q3 was 2.66 million yuan, a year-on-year decrease of 120.54% [1] - For the first three quarters, the company reported operating revenue of 526.89 million yuan, a year-on-year decrease of 17.03% [1] - The net loss attributable to shareholders for the first three quarters was 26.41 million yuan, a year-on-year decrease of 295.68% [1]

格隆汇10月30日丨皓宸医疗(002622.SZ)发布公告，2025年前三季度，实现营业收入5.27亿元，同比减少 17.03%；归属于上市公司股东的净利润-2640.98万元，归属于上市公司股东的扣除非经常性损益的净利 润-2452.45万元，基本每股收益-0.0314元。 ...

每经头条（nbdtoutiao）——多地出现"负电价"，既然卖电"不挣钱"，为何电厂不愿停机？ （记者 王晓波） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每经AI快讯，皓宸医疗（SZ 002622，收盘价：3.24元）10月30日晚间发布公告称，公司第五届第十六 次董事会会议于2025年10月30日在公司会议室以现场结合通讯表决方式召开。会议审议了《关于2025年 第三季度报告的议案》等文件。 2025年1至6月份，皓宸医疗的营业收入构成为：医疗口腔行业占比91.98%，开关占比7.69%，租赁业务 行业占比0.33%。 截至发稿，皓宸医疗市值为27亿元。 每日经济新闻 ...

（记者 胡玲） 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 每经AI快讯，皓宸医疗（SZ 002622，收盘价：3.24元）10月30日晚间发布三季度业绩公告称，2025年 前三季度营收约5.27亿元，同比减少17.03%；归属于上市公司股东的净利润亏损约2641万元；基本每股 收益亏损0.0314元。 截至发稿，皓宸医疗市值为27亿元。 每经头条（nbdtoutiao）——多地出现"负电价"，既然卖电"不挣钱"，为何电厂不愿停机？ ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥213,255,740.57, a decrease of 15.72% compared to the same period last year[5] - The net profit attributable to shareholders was -¥2,658,745.89, representing a decline of 120.54% year-on-year[5] - The basic earnings per share were -¥0.0031, down 120.13% from the previous year[5] - Total operating revenue decreased to ¥526,891,688.79 from ¥635,030,298.87, representing a decline of approximately 17.1% year-over-year[30] - Net profit for the period was a loss of ¥31,025,238.07 compared to a profit of ¥28,681,678.30 in the previous period, indicating a substantial decline[31] - Total comprehensive income for the period was -¥38,291,121.64, a significant drop from ¥30,221,773.21 in the prior year[32] - The company experienced a total loss of ¥28,257,351.48 in profit before tax, compared to a profit of ¥31,302,613.93 in the previous period[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,453,688,194.93, a decrease of 2.92% from the end of the previous year[5] - The company's total liabilities as of September 30, 2025, were CNY 1,042,562,022.36, down from CNY 1,054,436,349.33, indicating a reduction of about 1.1%[29] - The company's cash and cash equivalents decreased to CNY 125,287,409.13 from CNY 147,693,180.87, representing a decline of approximately 15.2%[27] - Accounts receivable fell to CNY 27,073,537.72 from CNY 39,169,433.88, a decrease of about 30.9%[27] - Inventory increased to CNY 57,657,756.69 from CNY 50,753,348.55, marking an increase of approximately 13.5%[27] - The company's total equity decreased to CNY 411,126,172.57 from CNY 443,047,294.21, reflecting a decline of about 7.2%[29] Research and Development - Research and development expenses increased by ¥606,000, or 108.60%, compared to the same period last year[9] - Research and development expenses increased significantly to ¥11,646,500.56 from ¥5,583,042.65, marking a rise of approximately 108.5% year-over-year[31] Cash Flow - The company reported a net cash flow from operating activities of -¥10,146,191.88, a decrease of 123.56% year-to-date[5] - The net cash flow from operating activities was negative at -¥10,146,191.88, a decrease from a positive cash flow of ¥43,066,291.87 in the prior year[34] - Cash and cash equivalents at the end of the period stood at ¥110,286,409.13, down from ¥152,382,007.24, reflecting a decrease of approximately 27.6%[34] Legal and Regulatory Issues - The company has disclosed multiple legal proceedings and updates related to the Jin Haitang case, with various court documents filed from 2020 to 2024[15] - The company has reported that it is in communication with the executing party and the Shanghai Financial Court regarding the Jin Haitang asset management case[16] - The company has faced asset freezes due to disputes with Zhejiang Zheshang Asset Management Co., Ltd. and Wenzhou Bank Co., Ltd.[21] - The company has not yet fulfilled its repayment obligations to Zhejiang Zheshang Asset Management Co., Ltd. and is exploring solutions to address its debt issues[21] - The company has disclosed that it has received a debt transfer notification from Zhejiang Zheshang Asset Management Co., Ltd. to Zhejiang Zheba Xianv Lake Enterprise Management Partnership[19] - The company has reported on the freezing of bank accounts and assets of its subsidiaries, with updates provided on various dates in 2023[18] Shareholder and Equity Changes - The total equity attributable to shareholders was ¥364,359,479.58, down 8.46% from the end of the previous year[5] - The number of ordinary shareholders at the end of the reporting period was 46,198[12] - The first major shareholder, 汇垠日丰, has become the sole trustee of a specific asset management plan, indicating a shift in control dynamics[23] - The company is actively preparing a detailed equity change report following recent court rulings affecting its control structure[24] - The company is actively seeking to negotiate with creditors regarding debt relief, extension, installment repayment, and financing replacement options[21] Investor Advisory - The company reminds investors to be aware of investment risks and to invest rationally[17] - Investors are advised to remain cautious and rational in their investment decisions due to ongoing uncertainties surrounding the company's control and financial performance[25]

Core Points - The company held its first extraordinary general meeting of shareholders in 2025, which was conducted legally and effectively [4][5][25] - The meeting involved a combination of on-site and online voting, with a total of 255 shareholders participating, representing 205,608,100 shares, or 24.4772% of the total voting shares [5][6][7] Meeting Details - The meeting took place on October 16, 2025, at 14:45 in Beijing [4] - The meeting was convened by the board of directors and chaired by the company's chairwoman, Ms. Lu Lu [4][9] Voting Participation - A total of 255 shareholders participated, with 3 attending in person and 252 voting online [5][6][7] - Among the participating shareholders, 251 were small investors, representing 5,575,100 shares, or 0.6637% of the total voting shares [8] Resolutions and Voting Results - The meeting approved several resolutions, including amendments to the company's articles of association, with 99.6450% of votes in favor [10][11] - Other resolutions, such as the rules for shareholder meetings and board meetings, also received overwhelming support, with approval rates exceeding 99% [12][14][19][21] Legal Compliance - The legal opinions provided by the law firm confirmed that the meeting's procedures complied with Chinese laws and regulations, ensuring the legitimacy of the voting process and results [25][26]